Douglas Lorne Arnold, MD, FRCP(C)

Citata da

	Tutte	Dal 2016
Citazioni	41215	15392
Indice H	108	53
i10-index	343	233

3600

1800

900

2700

1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021164 142 177 223 302 272 438 512 649 809 1036 1106 1043 1158 1276 1112 1231 1259 1299 1334 1350 1634 1892 2140 2235 2509 2925 2968 3147 3594 122

Coautori

Sridar Narayanan, PhDAssistant Professor: Department of Neurology and Neurosurgery, McGill UniversityEmail verificata su mcgill.ca
Amit Bar-OrProfessor, University of PennsylvaniaEmail verificata su pennmedicine.upenn.edu
Paul M. MatthewsEdmond and Lily Safra Chair, Professor of Clinical Neurosciences, Imperial College LondonEmail verificata su imperial.ac.uk
D. Louis CollinsProfessor of Biomedical Engineering and Neurology & Neurosurgery, McGill UniversityEmail verificata su mcgill.ca
Nicola De StefanoProfessor of Neurology, Universtiy of Siena,Email verificata su unisi.it
Zografos CaramanosMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill UniversityEmail verificata su mcgill.ca
Fernando CendesFull Professor, Department of Neurology, FCM, University of Campinas - UNICAMPEmail verificata su unicamp.br
Gavin GiovannoniBarts and The London School of Medicine and DentistryEmail verificata su giovannoni.net
Jerry S Wolinsky, MDProfessor Emeritus Neurology, McGovern Medical School, UTHealth, The University of Texas HealthEmail verificata su uth.tmc.edu
eric shoubridgeProfessor, Human Genetics, McGill UniversityEmail verificata su ericpc.mni.mcgill.ca
Li Min LiProfessor of Neurology, Faculty of Medical Sciences at University of CampinasEmail verificata su fcm.unicamp.br
Jeffrey A CohenCleveland ClinicEmail verificata su ccf.org
Robert J FoxMellen Center for Multiple Sclerosis, Cleveland ClinicEmail verificata su ccf.org
Bruce PikeCAIP Chair in Healthy Brain Aging, Hotchkiss Brain Institute, University of CalgaryEmail verificata su ucalgary.ca
John G. SledSenior Scientist, Hospital for Sick Children / Professor, University of TorontoEmail verificata su utoronto.ca
Carmela TartagliaAssociate Professor, University of TorontoEmail verificata su uhn.ca
Massimo FilippiSan Raffaele Scientific Institute, Vita-Salute San Raffaele UniversityEmail verificata su hsr.it
Robert A BrownUniversity of Calgary; Montreal Neurological InstituteEmail verificata su mcgill.ca
Alasdair ColesUniversity of CambridgeEmail verificata su medschl.cam.ac.uk
Emmanuelle WaubantProfessor of Neurology and PediatricsEmail verificata su ucsf.edu

Douglas Lorne Arnold, MD, FRCP(C)

James McGill Professor: Department of Neurology and Neurosurgery, Faculty of Medicine, McGill

Email verificata su mcgill.ca - Home page

Magnetic Resonance Imaging Neurological Disorders Multiple Sclerosis Alzheimer's Disease


Titolo Ordina per citazioni Ordina per anno Ordina per titolo	Citata da Citata da	Anno
B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008	2117	2008
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012	1461	2012
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... N Engl J Med 376 (3), 209-220, 2017	924	2017
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012	914	2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012	911	2012
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... N Engl J Med 376 (3), 221-234, 2017	809	2017
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy MC Preul, Z Caramanos, DL Collins, JG Villemure, R Leblanc, A Olivier, ... Nature medicine 2 (3), 1996	620	1996
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability N De Stefano, S Narayanan, GS Francis, R Arnaoutelis, MC Tartaglia, ... Archives of neurology 58 (1), 65-70, 2001	582	2001
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study N De Stefano, PM Matthews, L Fu, S Narayanan, J Stanley, GS Francis, ... Brain 121 (Pt 8), 1469-1477, 1998	563	1998
Imaging axonal damage of normal-appearing white matter in multiple sclerosis L Fu, PM Matthews, N De Stefano, KJ Worsley, S Narayanan, GS Francis, ... Brain 121 (1), 103-113, 1998	556	1998
Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR DL Arnold, PM Matthews, GK Radda Magnetic resonance in medicine 1 (3), 307-315, 1984	517	1984
Reversible decreases in N‐acetylaspartate after acute brain injury ND Stefano, PM Matthews, DL Arnold Magnetic Resonance in Medicine 34 (5), 721-727, 1995	497	1995
Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region N Bernasconi, A Bernasconi, Z Caramanos, SB Antel, F Andermann, ... Brain 126 (2), 462-469, 2003	480	2003
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008	457	2008
Energetics of human muscle: exercise-induced ATP depletion DJ Taylor, P Styles, PM Matthews, DL Arnold, DG Gadian, P Bore, ... Magn Reson Med 3 (1), 44-54, 1986	370	1986
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques DL Arnold, PM Matthews, GS Francis, J O'Connor, JP Antel Annals of Neurology: Official Journal of the American Neurological …, 1992	366	1992
Chemical pathology of acute demyelinating lesions and its correlation with disability N De Stefano, PM Matthews, JP Antel, M Preul, G Francis, DL Arnold Annals of neurology 38 (6), 901-909, 1995	361	1995
Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis H Reddy, S Narayanan, R Arnoutelis, M Jenkinson, J Antel, PM Matthews, ... Brain 123 (11), 2314-2320, 2000	353	2000
Myoblast transfer in Duchenne muscular dystrophy G Karpati, D Ajdukovic, D Arnold, RB Gledhill, R Guttmann, P Holland, ... Annals of Neurology: Official Journal of the American Neurological …, 1993	348	1993
Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease DL Arnold, PM Matthews, G Francis, J Antel Magnetic resonance in medicine 14 (1), 154-159, 1990	344	1990

Il sistema al momento non può eseguire l'operazione. Riprova più tardi.

Articoli 1–20

Citazioni per anno

Citazioni duplicate

Citazioni unite

Aggiungi coautoriCoautori

Carica PDF

Segui questo autore

Citata da

Coautori